
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HS235
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Details : HS235 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2025
Lead Product(s) : HS235
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HS235
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of HS235 in Obese Patients with Pulmonary Hypertension & HFpEF
Details : HS235 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 14, 2025
Lead Product(s) : HS235
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HS235
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HS235 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : HS235
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Frazier Life Sciences
Deal Size : $53.0 million
Deal Type : Series C Financing
35Pharma Closes Series C Funding for Activin Inhibitors in Pulmonary Diseases
Details : The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
November 26, 2024
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Frazier Life Sciences
Deal Size : $53.0 million
Deal Type : Series C Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HS135 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure, Diastolic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 03, 2024
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
Details : HS135 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 10, 2024
Lead Product(s) : HS135
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
